Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director · Chief Executive Officer | March 11, 2022 | March 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INOVIO PHARMACEUTICALS, INC.
Report date March 11, 2022 · Filed March 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,422,627 |
Ending reported balance
After 2022-03-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-11 · Exercise / conversion · Acquired 139,387 · Balance 1,462,325 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Row 2 · 2022-03-11 · Tax withholding · Disposed 39,698 · Balance 1,422,627 F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 139,386 |
Reported balance
After 2022-03-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-03-11 · Exercise / conversion · Disposed 139,387 · Balance 139,386 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Limited Partnership | 816,527 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 816,527 |
| Common StockSEC Table I · non-derivative | IndirectBy Daughter: EK | 33,563 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 33,563 |
| Common StockSEC Table I · non-derivative | IndirectBy Son: JK1 | 33,775 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 33,775 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 5,975 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,975 |
| Common StockSEC Table I · non-derivative | IndirectBy Son: JK2 | 33,533 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 33,533 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2019 Filed Mar 12, 2019 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 16,329 | $3.34 | $54,538.86 |
DisclosureSEC source: 0001055726-19-000015 · wf-form4_155242488364573.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,435,459 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units award reported in footnote (1) herein. Read SEC document |
| March 09, 2019 Filed Mar 12, 2019 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 57,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-19-000015 · wf-form4_155242488364573.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,451,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units was as follows: 57,334 shares vested on March 9, 2017; 57,333 shares vested on March 9, 2018; 57,333 shares vested on March 9, 2019. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 191,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000015 · wf-form4_155242488364573.xml · derivative · entry 13 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,100 Underlying: Common Stock · 191,100 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares will vest on March 8, 2020; 63,700 shares will vest on March 8, 2021; 63,700 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares will vest on March 8, 2020; 63,700 shares will vest on March 8, 2021; 63,700 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 191,100 restricted stock units is as follows: 63,700 shares will vest on March 8, 2020; 63,700 shares will vest on March 8, 2021; 63,700 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 298,100 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0001055726-19-000015 · wf-form4_155242488364573.xml · derivative · entry 12 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,100 Underlying: Common Stock · 298,100 shares Expires 2029-03-08 F5 · derivative.exercise_date: The vesting schedule for the 298,100 options is as follows: 74,525 shares vested on March 8, 2019; 74,525 shares will vest on March 8, 2020; 74,525 shares will vest on March 8, 2021; 74,525 shares will vest on March 8, 2022. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 22:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 120,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000007 · wf-form4_155199657903918.xml · derivative · entry 8 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,200 Underlying: Common Stock · 120,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares will vest on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares will vest on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares will vest on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares will vest on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 22:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 34,139 | $3.61 | $123,241.79 |
DisclosureSEC source: 0001055726-19-000007 · wf-form4_155199657903918.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,394,455 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 22:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 120,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-19-000007 · wf-form4_155199657903918.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,428,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares will vest on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 21:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 49,060 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001055726-18-000042 · wf-form4_153695955718652.xml · derivative · entry 8 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,060 shares Expires 2018-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 21:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 49,060 | $5.37 | $263,452.20 |
DisclosureSEC source: 0001055726-18-000042 · wf-form4_153695955718652.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,308,494 F1 · price: This transaction was executed in multiple trades at prices ranging from $5.32 to $5.44, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 21:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 49,060 | $5.08 | $249,224.80 |
DisclosureSEC source: 0001055726-18-000042 · wf-form4_153695955718652.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,357,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2018 Filed May 9, 2018 22:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 23,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-18-000027 · wf-form4_152590379716247.xml · derivative · entry 8 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the original 70,000 restricted stock units granted was as follows: 23,334 shares vested on May 8, 2016; 23,333 shares vested on May 8, 2017; and 23,333 shares vested on May 8, 2018. Vested units of restricted stock could have been settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the original 70,000 restricted stock units granted was as follows: 23,334 shares vested on May 8, 2016; 23,333 shares vested on May 8, 2017; and 23,333 shares vested on May 8, 2018. Vested units of restricted stock could have been settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the original 70,000 restricted stock units granted was as follows: 23,334 shares vested on May 8, 2016; 23,333 shares vested on May 8, 2017; and 23,333 shares vested on May 8, 2018. Vested units of restricted stock could have been settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 08, 2018 Filed May 9, 2018 22:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 6,646 | $4.68 | $31,103.28 |
DisclosureSEC source: 0001055726-18-000027 · wf-form4_152590379716247.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,308,494 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| May 08, 2018 Filed May 9, 2018 22:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 23,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000027 · wf-form4_152590379716247.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,315,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the original 70,000 restricted stock units granted was as follows: 23,334 shares vested on May 8, 2016; 23,333 shares vested on May 8, 2017; and 23,333 shares vested on May 8, 2018. Vested units of restricted stock could have been settled in shares of common stock, cash or a combination of both. Read SEC document |
| April 13, 2018 Filed Apr 13, 2018 22:35 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 107,500 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001055726-18-000022 · wf-form4_152365890387009.xml · derivative · entry 11 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,500 shares Expires 2023-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2018 Filed Apr 13, 2018 22:35 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 107,500 | $5.06 | $543,412.50 |
DisclosureSEC source: 0001055726-18-000022 · wf-form4_152365890387009.xml · nonDerivative · entry 4 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,291,807 Read SEC document |
| April 13, 2018 Filed Apr 13, 2018 22:35 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 107,500 | $2.16 | $232,200.00 |
DisclosureSEC source: 0001055726-18-000022 · wf-form4_152365890387009.xml · nonDerivative · entry 3 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,399,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2018 Filed Apr 13, 2018 22:35 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 103,750 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001055726-18-000022 · wf-form4_152365890387009.xml · derivative · entry 10 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,750 shares Expires 2022-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2018 Filed Apr 13, 2018 22:35 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 103,750 | $5.14 | $533,140.13 |
DisclosureSEC source: 0001055726-18-000022 · wf-form4_152365890387009.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,291,807 Read SEC document |
| April 12, 2018 Filed Apr 13, 2018 22:35 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 103,750 | $2.40 | $249,000.00 |
DisclosureSEC source: 0001055726-18-000022 · wf-form4_152365890387009.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,395,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2018 Filed Mar 13, 2018 22:34 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 105,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000008 · wf-form4_152098044956325.xml · derivative · entry 11 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,400 Underlying: Common Stock · 105,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares will vest on March 10, 2019; 105,700 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares will vest on March 10, 2019; 105,700 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares will vest on March 10, 2019; 105,700 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares will vest on March 10, 2019; 105,700 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 10, 2018 Filed Mar 13, 2018 22:34 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 30,104 | $4.51 | $135,769.04 |
DisclosureSEC source: 0001055726-18-000008 · wf-form4_152098044956325.xml · nonDerivative · entry 4 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,291,807 F4 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (3) herein. Read SEC document |
| March 10, 2018 Filed Mar 13, 2018 22:34 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 105,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000008 · wf-form4_152098044956325.xml · nonDerivative · entry 3 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,321,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares vested on March 10, 2018; 105,700 shares will vest on March 10, 2019; 105,700 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 22:34 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 57,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000008 · wf-form4_152098044956325.xml · derivative · entry 10 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,333 Underlying: Common Stock · 57,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units is as follows: 57,334 shares vested on March 9, 2017; 57,333 shares vested on March 9, 2018; 57,333 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units is as follows: 57,334 shares vested on March 9, 2017; 57,333 shares vested on March 9, 2018; 57,333 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units is as follows: 57,334 shares vested on March 9, 2017; 57,333 shares vested on March 9, 2018; 57,333 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units is as follows: 57,334 shares vested on March 9, 2017; 57,333 shares vested on March 9, 2018; 57,333 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 22:34 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 15,944 | $4.51 | $71,907.44 |
DisclosureSEC source: 0001055726-18-000008 · wf-form4_152098044956325.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,216,211 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 22:34 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 57,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000008 · wf-form4_152098044956325.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,232,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units is as follows: 57,334 shares vested on March 9, 2017; 57,333 shares vested on March 9, 2018; 57,333 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 00:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 360,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-18-000002 · wf-form4_152046965167200.xml · derivative · entry 10 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,300 Underlying: Common Stock · 360,300 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares will vest on March 5, 2019; 120,100 shares will vest on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares will vest on March 5, 2019; 120,100 shares will vest on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares will vest on March 5, 2019; 120,100 shares will vest on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 00:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 138,250 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001055726-18-000002 · wf-form4_152046965167200.xml · derivative · entry 9 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,250 Underlying: Common Stock · 138,250 shares Expires 2028-03-05 F3 · derivative.exercise_date: The vesting schedule for the 138,250 options is as follows: 34,563 shares vested on March 5, 2018; 34,563 shares will vest on March 5, 2019; 34,562 shares will vest on March 5, 2020; 34,562 shares will vest on March 5, 2021. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 00:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 13,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000002 · wf-form4_152046965167200.xml · derivative · entry 8 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 40,000 restricted stock units was as follows: 13,334 shares vested on March 5, 2016; 13,333 shares vested on March 5, 2017; 13,333 shares vested on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 40,000 restricted stock units was as follows: 13,334 shares vested on March 5, 2016; 13,333 shares vested on March 5, 2017; 13,333 shares vested on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 40,000 restricted stock units was as follows: 13,334 shares vested on March 5, 2016; 13,333 shares vested on March 5, 2017; 13,333 shares vested on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 40,000 restricted stock units was as follows: 13,334 shares vested on March 5, 2016; 13,333 shares vested on March 5, 2017; 13,333 shares vested on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 00:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 3,711 | $4.29 | $15,920.19 |
DisclosureSEC source: 0001055726-18-000002 · wf-form4_152046965167200.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,174,822 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 00:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 13,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000002 · wf-form4_152046965167200.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,178,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 40,000 restricted stock units was as follows: 13,334 shares vested on March 5, 2016; 13,333 shares vested on March 5, 2017; 13,333 shares vested on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 18:26 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 61,325 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001055726-17-000033 · wf-form4_150161198347248.xml · derivative · entry 7 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,325 shares Expires 2017-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 18:26 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 61,325 | $5.08 | $311,531.00 |
DisclosureSEC source: 0001055726-17-000033 · wf-form4_150161198347248.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,165,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2017 Filed May 9, 2017 23:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 23,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-17-000022 · wf-form4_149437345893121.xml · derivative · entry 8 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,333 Underlying: Common Stock · 23,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 70,000 restricted stock units is as follows: 23,334 shares vested on May 8, 2016; 23,333 shares vested on May 8, 2017; 23,333 shares will vest on May 8, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 70,000 restricted stock units is as follows: 23,334 shares vested on May 8, 2016; 23,333 shares vested on May 8, 2017; 23,333 shares will vest on May 8, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 70,000 restricted stock units is as follows: 23,334 shares vested on May 8, 2016; 23,333 shares vested on May 8, 2017; 23,333 shares will vest on May 8, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 70,000 restricted stock units is as follows: 23,334 shares vested on May 8, 2016; 23,333 shares vested on May 8, 2017; 23,333 shares will vest on May 8, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 08, 2017 Filed May 9, 2017 23:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 10,755 | $6.29 | $67,648.95 |
DisclosureSEC source: 0001055726-17-000022 · wf-form4_149437345893121.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,103,875 Read SEC document |
| May 08, 2017 Filed May 9, 2017 23:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 23,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-17-000022 · wf-form4_149437345893121.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,114,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 70,000 restricted stock units is as follows: 23,334 shares vested on May 8, 2016; 23,333 shares vested on May 8, 2017; 23,333 shares will vest on May 8, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 73,590 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001055726-17-000020 · wf-form4_149125372438902.xml · derivative · entry 11 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,590 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The term of these stock option was extended by 14 days after the expiration of the Company's blackout period. F1 · derivative.expiration_date: The term of these stock option was extended by 14 days after the expiration of the Company's blackout period. Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 73,590 | $6.57 | $483,773.30 |
DisclosureSEC source: 0001055726-17-000020 · wf-form4_149125372438902.xml · nonDerivative · entry 4 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,091,297 Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 73,590 | $5.08 | $373,837.20 |
DisclosureSEC source: 0001055726-17-000020 · wf-form4_149125372438902.xml · nonDerivative · entry 3 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,164,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 73,590 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001055726-17-000020 · wf-form4_149125372438902.xml · derivative · entry 10 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,590 Underlying: Common Stock · 73,590 shares Expires 2017-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The term of these stock option was extended by 14 days after the expiration of the Company's blackout period. F1 · derivative.expiration_date: The term of these stock option was extended by 14 days after the expiration of the Company's blackout period. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 73,590 | $6.51 | $478,710.31 |
DisclosureSEC source: 0001055726-17-000020 · wf-form4_149125372438902.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,091,297 Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 73,590 | $5.08 | $373,837.20 |
DisclosureSEC source: 0001055726-17-000020 · wf-form4_149125372438902.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,164,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2017 Filed Mar 13, 2017 21:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 317,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-17-000008 · wf-form4_148944129682642.xml · derivative · entry 12 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,100 Underlying: Common Stock · 317,100 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares will vest on March 10, 2018; 105,700 shares will vest on March 10, 2019; 105,700 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares will vest on March 10, 2018; 105,700 shares will vest on March 10, 2019; 105,700 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 317,100 restricted stock units is as follows: 105,700 shares will vest on March 10, 2018; 105,700 shares will vest on March 10, 2019; 105,700 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 10, 2017 Filed Mar 13, 2017 21:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 43,150 | $6.68 Strike: $6.68 | $288,242.00 |
DisclosureSEC source: 0001055726-17-000008 · wf-form4_148944129682642.xml · derivative · entry 11 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,150 Underlying: Common Stock · 43,150 shares Expires 2027-03-10 F3 · derivative.exercise_date: The vesting schedule for the 43,150 options is as follows: 10,787 shares vested on March 10, 2017; 10,788 shares will vest on March 10, 2018; 10,787 shares will vest on March 10, 2019; 10,788 shares will vest on March 10, 2020. Read SEC document |
| March 10, 2017 Filed Mar 13, 2017 21:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 52,605 | $6.68 | $351,401.40 |
DisclosureSEC source: 0001055726-17-000008 · wf-form4_148944129682642.xml · nonDerivative · entry 4 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,091,297 Read SEC document |
| March 10, 2017 Filed Mar 13, 2017 21:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 139,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-17-000008 · wf-form4_148944129682642.xml · nonDerivative · entry 3 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,143,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These restricted stock units vested 100% on the March 10, 2017 grant date. Read SEC document |
| March 09, 2017 Filed Mar 13, 2017 21:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 57,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-17-000008 · wf-form4_148944129682642.xml · derivative · entry 10 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,666 Underlying: Common Stock · 57,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units is as follows: 57,334 vested on March 9, 2017; 57,333 shares will vest on March 9, 2018; 57,333 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units is as follows: 57,334 vested on March 9, 2017; 57,333 shares will vest on March 9, 2018; 57,333 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units is as follows: 57,334 vested on March 9, 2017; 57,333 shares will vest on March 9, 2018; 57,333 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units is as follows: 57,334 vested on March 9, 2017; 57,333 shares will vest on March 9, 2018; 57,333 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 09, 2017 Filed Mar 13, 2017 21:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 17,787 | $6.61 | $117,572.07 |
DisclosureSEC source: 0001055726-17-000008 · wf-form4_148944129682642.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,004,157 Read SEC document |
| March 09, 2017 Filed Mar 13, 2017 21:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 57,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-17-000008 · wf-form4_148944129682642.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,021,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 172,000 restricted stock units is as follows: 57,334 vested on March 9, 2017; 57,333 shares will vest on March 9, 2018; 57,333 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 21:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 4,365 | $6.95 | $30,336.75 |
DisclosureSEC source: 0001055726-17-000002 · wf-form4_148892288607267.xml · nonDerivative · entry 2 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,964,610 Read SEC document |
| March 05, 2017 Filed Mar 7, 2017 21:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 13,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-17-000002 · wf-form4_148892288607267.xml · derivative · entry 8 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 13,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 40,000 restricted stock units is as follows: 13,334 shares vested on March 5, 2016; 13,333 shares vested on March 5, 2017; 13,333 shares will vest on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 40,000 restricted stock units is as follows: 13,334 shares vested on March 5, 2016; 13,333 shares vested on March 5, 2017; 13,333 shares will vest on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 40,000 restricted stock units is as follows: 13,334 shares vested on March 5, 2016; 13,333 shares vested on March 5, 2017; 13,333 shares will vest on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 40,000 restricted stock units is as follows: 13,334 shares vested on March 5, 2016; 13,333 shares vested on March 5, 2017; 13,333 shares will vest on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.